Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
11121-32-7
Molecular formula
C119H174N4O38
Molecular weight
2268.7 g/mol
Drug class
Polyene macrolide antibioticantifungal and antiprotozoal agent
Mechanism of action
A polyene macrolide antibiotic complex derived from Streptomyces aureofaciens. Like other polyenes, it is associated with interaction with sterol-containing biological membranes, although the exact composition and detailed mechanism of mepartricin are not fully characterised.
Indications / reported uses
Used in some countries for selected urological indications, including benign prostatic hyperplasia, and historically for antifungal or antiprotozoal purposes; indications and availability vary by jurisdiction.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Mepartricin PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Mepartricin Permitted Daily Exposure (PDE) report (the Mepartricin PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Mepartricin Occupational Exposure Limit (OEL) report (the Mepartricin OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.